Login to Your Account



AC Immune Drops ACI-91 on Phase II Alzheimer's Failure

By Cormac Sheridan
Staff Writer

Friday, February 1, 2013
The drug development graveyard that is Alzheimer's disease has claimed yet another victim. This time it's AC Immune SA's ACI-91, a drug that had offered a new approach to tackling this most intractable of diseases.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription